DOCSLIB.ORG

Author Index Page Numbers in Italics Refer to the Bibliography

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Author Index Page Numbers in Italics Refer to the Bibliography Author Index Page numbers in italics refer to the bibliography Abbs, E. T., Broadley, K. J., Ahlquist, R. P., Levy, B. 285, Allegranza, A., see Bozzi, R., Roberts, D. J. 506, 518 298,330 855, 884 - Robertson, M.1. 777, 803 Ahmed, R., see Pullar, I. A. Allen, D. J., Garg, K. N., Mar­ Abdulla, Y. H., see Adams, C. 859, 872, 873, 894 ley, E. 491, 492, 493, iH8 W. M. 48, 72 Aigner, A., Hornykiewicz, 0., - Marley, E. 484, 485, 491, Abe, K., Butcher, R. W., Ni­ Lisch, H.-J., Springer, A. 509,518 cholson, W. E., Baird, C. 504,518 Allen, D.O., Hillman, C. C., E., Liddle, R. A., Liddle, - see Lisch, H.-J. 148, 179 Ashmore, J. 301, 302, 330, G. W. 434, 441 Aiken, J. W., Reit, E. 662, 715 387,441 Abel, J. J., Crawford, A. C. Akabane, J., Nakanishi, S., Allen, G., see Friesen, A. J. D. 1l0,171 Kohei, H., Asakawa, S., 394,398,447 - De M. Taveau, R. 1l0, 171 Matsumura, R. Ogata, H., Allen, M. L., see Himwich, W. - Macht, D. I. 114, 171 Miyazawa, T. 587, 605 A. 465, 528 Abood, L. G., Koketsu, K., Akawie, R. I., see Hartman, Aim, P., Ehinger, B., Falck, B. Miyamoto, S. 256, 261 W. J. 191, 224, 853, 867, 871,881 Abrams, W. B., Solomon, H. 880,889 Almgren, 0., Anden, N.-E., M. 873,881 Akester, A. R., Mann, S. P. Jonason, J., Norberg,K.-A., - see Leon, A. S. 873, 891 117,171 Olson, L. 752, 756 - see Solomon, H. M. 873, Akimoto, H., see Inoue, M. -- Waldeck, B. 621, 626, 879,897 140,178 652 Abuzzahab, F. S. 495, 518 Alberici, M., Rodriguez de Lo­ - Lundborg, P. G., Stitzel, R. Acheson, G. H. 729, 756 res Arnaiz, G., de Robertis, E. 621, 652 - Remolina, J. 689, 715 E. 504, 518 - Waldeck, B. 621, 630, 652 Ackermann, H., see Lange- - see De Robertis, E. 427, 446 Alonso-de Florida, F., see Par­ mann, H. 854, 891 Albers, R. W., see Axelrod, J. do, E. G. 783, 811 Adam, P. A. J., Haynes, R. C., 272, 279, 816, 835 Alousi, A., Weiner, N. 194,219 jr. 372, 377, 441 Albert, A. 193, 219, 464, 518 Alper, M. R., see Gillis, R. A. Albores-Saavedra, J., Maldo­ 685,718 Adams, C. W. M., Abdulla, Y. nado, M. C., Ibara, J., Ro- - see Krayer, O. 355, 359 H., Bayliss, O. B. 48, 72 driguez, H. A. 909, 924 Alpers, H. S., see Crout, J. R. Adams, W. E. 22, 39 Albrecht, I., see Hruza, Z. 170, 625, 630, 631, 632, 633, 641, Adams-Ray, J. 131,171 178 653 - Dahlstrom, A., Fuxe, K., Alcaraz, A., see Masuoka, D. - see Shore, P. A., 497, 535, Haggendal, J. 25, 39 T. 626, 656 619,621,622,625,628,637, --- Hillarp, N.-A. 133, Aldrich, T. B. 1l0, 171 638,658 171 Aldridge, J., Bradley, P. B. 477 Altland, P. D., see Stern, D. N. - Nordenstam, H. 24, 39 Aldridge, W. N., Street, B. W. 814,842 - see Bloom, G. 18, 40, 113, 411, 412, 441 Altman, M., see Sapira, J. P. 134,172 Alexander, N., see De Quattro, 901,931 - see Ostlund, E. 134, 181 V.194,222 Alton, H., see Goodall, McC. Adanja, 8., see Mi6i6, R. 902, Alexandrowicz, J. S. 100,105 855,888 929 Alfes, H., see Knoche, H. 113, Alvarez, N., see Drujan, B. D. Mzelius, B. A., see Lindberg, 130,179 141,157,174 0.412,453 Algeri, S., see Bloom, F. E. 47, Amador, L. V., see Schwab, R. Agallianos, D., see Messiha, F. 64,67,72 S.863,895 S.855,892 - see Groppetti, A. 857, 888 Amakawa, A., see Shimazu, T. Aghajanian, G. K., Bloom, F. - see Manara, L. 500, 531 370, 371, 459 E. 61, 63, 72 AI-Lami, F. 600, 601, 605 Amalfara, M. L., see Fischer, - see Bloom, F. E. 46, 50, 61, Allan, W., Tepperman, H. M. E. 471, 525 63,64,71,72 422,441 Amar-Costesec, A., Bohuon, C., Agrawal, H. C., Glisson, S. N., Allegra, F., Marcheselli, W. 25, Schweissguth, O. 904, 917, Himwich, W. A. 118, 171 39 924 Ahlquist, R. P. 9, 11, 285, 286, Allegranza, A., Bozzi, R., Bru­ - see Bohuon, C. 917, 924 330,814,835 no, A. 236, 261 Ambache, N. 766, 803 Author Index 935 Ambrose, J. M., see Engelman, Anden, N.-E., Norberg, K. A., Anton, A. H., Gennaro, J. F. K. 914, 925 Olson, L. 129,166,171 116, 142,171 Amery, A., Moerman, E. J., - Roos, B. E., Werdinius, B. - Greer, M., Sayre, D. F., BOBBaert, H., de Schaepdry­ 498, 518, 519, 855, 859, 881 Williams, C. M., 852, 881, ver, A. F. 627, 652, 916, 924 - see Almgren, O. 621, 626, 905, 911, 913, 918, 924 Amin, A. N., Crawford, T. B. 652,752,756 - Sayre, D. F. 112, 116, 118, B., Gaddum, J. H. 486, 518 - see Ungerstedt, U. 506, 537, 119,131,140,142,144,147, Ammon, H. P. T., see Estier, 854,898 149, 154, 159, 160, 161, 163, C.J.496,524 Andersen, H. T., Andersson, 164, 166, 167,171 Amsterdam, A., Ohad, 1., B., Gale, C. 490, 519 - see Greer, M. 918, 920, 921, Schramm, M. 423, 441, 589, Andersen, S. 0., 85, 109 927 597,605 - Barrett, F. M. 85 Antonaccio, M. J., Smith, C. B. Anagnoste, B., Goldstein, M. Anderson, E. 52, 72 752,756 881 Anderson, E. G., Baker, R. G., Antunes, J. L., Macedo, C., Da­ - see Battista, A. F. 847, 882 Banna, N. R. 517, 519 masio, A. R. 862, 881 - see Goldstein, M. 193, 201, - Holgerson, L. O. 119, 154, - see Damasio, A. R. 865, 886 223,501,503,526,628,654, 171 Apelbaum, J., see Segura, E. T. 814,838,847,850,863,874, - see Baker, R. G. 518, 519 115,183 880,887,888,917,926 Anderson, H. K. 832, 835 Appel, W. C., Vincenzi, F. F. - see Musacchio, J. M. 503, Anderson, P. J., D'Iorio, A. 765,803 532 858,881 Appelgren, L. E., see Elfvin, Anah, C. 0., see Ruthven, C. R. AnderBBon, B., Grant, R., Lars­ L.-G. 31, 41, 52, 68, 74 J. 874, 894 son, S. 494, 519 Appleman, M. M., Birnbaumer, Anand, B. K. 489, 518 - Jobin, M., Olsson, K. 484, L., Torres, H. N. 401, 404, - Brobeck, J. R. 489, 519 519 441 - Dua, S.489, 519 - Larsson, B. 490, 519 - see Belocopitow, E. 403, 442 Anden, N.-E. 119, 171, 197, - see Andersen, H. T. 490, 519 Applewhite, P. B., Gardner, F. 200,206,219,497,519,619, Andersson, R. G. G., Mohme­ T., Lapan, E. 81, 85, 105 625,628,636,637,638,639, Lundholm, E. 406, 441 April, S. A., see Salvador, R. A. 652 Andrews, R. S., Pridham, J. B. 286,334,423,458 - Butcher, S. G., Corrodi, H., 852,881 Aprison, M. H., Takahashi, R. Fuxe, K., Ungerstedt, U. Andrews, W. H. H. 709, 715 144, 147,171 854,881 - see Nasmyth, P. A. 211, Arakowa, T., Wada, Y., Tada, -- Engel, J. 878, 881 227 K., Ito, H. 852, 881 -- Fuxe,K. 878,881 Angel, A., Rogers, K. J. 506, Arana, R., see Leimdorfer, A. - Carlsson, A., Dahlstrom, A., 519 470,471,530 Fuxe, K., Hillarp, N.-A., Angelakos, E. T., Fuxe, K., Archer, S., Arnold, A., Kullnig, Larsson, K. 847, 881 Torchiana, M. L. 125, 159, R. K., Wylie, D. W. 506, -- Kerstell, J., Magnusson, 171, 188, 201, 219 519 T., OIBBon, R., Roos, B. E., - Glassman, P. M., Millard, R. - see Wylie, D. W. 273, 282, Steen, B., Steg, G., Svan­ W., King, M. 115, 137, 139, 759,761 borg, A., Thieme, G., Wer­ 140,171 Arias, D., see Tamer, A. 848, dinius, B. 865, 866, 872, 874, - King, M., Millard, R.W. 897 875,881 160,171 Ariens, E. J. 288, 289, 302, 323, -- Waldeck, B. 199, 209, - see McKenna, O. C. 126, 330 219 161,180 - see Van Rossum, J. M. 288, - Corrodi, H., Ettles, M., Angeletti, P., Calissano, P., 335 Gustafsson, E., Persson, H. Chen, J. S., Levi-Montalci­ Arimura, A., see Couch, E. F. 197, 198, 206, 219, 737, ni, R. 819, 829, 835 563,607 756 - see Levi-Montalcini, R. 11, Armett, C. J., Ritchie, J. M. - Fuxe, K., Hamberger, B., 14, 167, 179, 814, 819, 820, 703,706,715,765,803 Hokfelt, T. 149,171 821, 822, 830, 831, 840 Armitage, P., see CaIne, D. B. -- Henning, M. 641, 642, Angeletti, P. U., see Salvi, M. 861, 865, 873, 884 652 L. 819, 841 - see Hunter, K. R. 869, 870, -- Hokfelt, T. 641, 652 Anlyan, W. G., Hargrove, M. 890 - Henning, M. 157, 171, 236, D., jr., Ruffin, J. M., Wal­ Armstrong, M. D., McMillan, A. 261 lace, D. K., Weaver, W. T., 193,219 - Jukes, M. G. M., Lundberg, Kirshner, N. 861, 881 -- Shaw, K. F. 6, 11, 270, A. 518, 519 Ansel, R. D., Markham, C. H. 272,279,848,881,912,924 --- Vyklicky, L, 518,519 863,865,881 - see Kakimoto, Y. 189, 225, - Magnusson, T. 206, 219, - see Markham, C. H. 863, 629,655 495,498,519,625,637,644, 892 - see Shaw, K. N. F. 270, 281, 652 Anthony, P. P., Coles, H. M. T., 874,896 -- Rosengren, E. 813, 816, Pryse-Davies, J., Sinclair, Arner, P., see Ostman, J. 386, 828,835 L. 917, 919, 924 387,455 936 Author Index Arnold, A., McAuliff, J. P. 320, Auditore, J. V., see Hollett, C. Axelrod. J., see Hertting, G. 321,330,387,440,441 R.
Load more

Recommended publications
  • LIGAND FORMULA INDEX CH5N 1 C3hlln3 68 CH603NP Z97 C3hll
    LIGAND FORMULA INDEX CH5N 1 C3HllN3 68 CH 0 NP Z97 6 3 C3Hll °3Nl 304 C3HIZ0gNP3 319 C H O N 164 Z 3 Z 3 C3HIZ0l0NP3 3Z0 CZH4OZN4 164 C H N 335 Z 5 C4H304N3 343 C H 0 N 347 Z 5 Z Z C4H4NZ 263,263,264 C H 0N Z6 Z 6 Z C4H402N2 34Z C H O N Z 6 Z 4 56 C4H403NZ 34Z C H N Z,72 2 7 C4H5ON Z 264 C H NS 3Z Z 7 C4H6NZ 146,148,149,349 C H 0N 15 Z 7 C4H6ON Z 15Z,15Z C H 0 NS 10 Z 7 3 C4H7N3 155 C H 0 NS 331 Z 7 4 C4H9N 7,73 C H N 36 2 8 Z C4HgN3 S2 348 C H 0 NP Z 8 3 Z98,246 C4HgON 81 C H 0 NP 3Z9 Z 8 4 C4HgON 2 348 C4HgOZN Z4,333,333 C H N 144,349 3 4 Z C4HgOZNS 33 C3H7N 6,331,335 C4H9OZN3 28,348 C H 0 N 23 3 7 2 C4Hg03 N 18 C3H80N 79 C4H904N2 77 Z7,3L,7 C3H80N2 C4H10NZ 91 3,331 C3HgN C4Hl00ZNZ 59 33,%7 C3H9NS C4H1006NP 346 347 C3HgN3 S C4HllN 3,5,7Z,331,331 C H ON 3 g 16,16,21 C4Hll NS 348 C H O N 347 3 g Z C4HllON 17,79,115,33Z,33Z,347 10 C3Hg03 NS C4HllONS 35 C H N 39,51,8Z 3 10 Z C4HllOZN 19,80 C H ON 57 3 10 Z C4Hl103N ZO 298,300,301 C3HIOO3 NP C4Hll03NS 11 393 394 LIGAND FORMULA INDEX C4H1ZN2 40,40,41,42,S2,S4,83,88,lZ0 CsHn 02N3 29,29 C4H12N2S 6S C5H12NZ 91,92,124 C4H12NZS2 66 CSH120NZ 14 C4H1ZON 2 S8,9S CSH1202NZ 334 C4H1Z03NP Z99,346 CSH13N 4,331,33S C4H13N3 69,101 CSH130N 17,337 C4H1306NPZ 318 CSH130ZN 117,336,347 C4H1404Nl2 Z93 CSH1303NS 11 C4H1406NZPZ 30S CSH14NZ S3,SS,84,84,92,337 CSH140N Z 96,97,348,348 CSH3N4Cl 344 CSH1403NP 317,346 CSH4NBr 340,340 CSH140SNP 317 CSH4NCI 340,340 CSHlSN3 103,103 CSH4N4 344 CSH16 N4 71 CSH4N4S 344 CSH1709Nl3 346 CSH40N4 34S CSH40ZN4 34S C6H4N2 177,177 CSHSN 16S C6H4ON4 3S3 CSHSNS 276 C6H402N4 3S3 CSHSNSS
    [Show full text]
  • Radiolabelled Molecules for Brain Imaging with PET and SPECT • Peter Brust Radiolabelled Molecules for Brain Imaging with PET and SPECT
    Radiolabelled Molecules for Brain Imaging with PET and SPECT Radiolabelled • Peter Brust Molecules for Brain Imaging with PET and SPECT Edited by Peter Brust Printed Edition of the Special Issue Published in Molecules www.mdpi.com/journal/molecules Radiolabelled Molecules for Brain Imaging with PET and SPECT Radiolabelled Molecules for Brain Imaging with PET and SPECT Editor Peter Brust MDPI • Basel • Beijing • Wuhan • Barcelona • Belgrade • Manchester • Tokyo • Cluj • Tianjin Editor Peter Brust Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf Germany Editorial Office MDPI St. Alban-Anlage 66 4052 Basel, Switzerland This is a reprint of articles from the Special Issue published online in the open access journal Molecules (ISSN 1420-3049) (available at: https://www.mdpi.com/journal/molecules/special issues/PET SPECT). For citation purposes, cite each article independently as indicated on the article page online and as indicated below: LastName, A.A.; LastName, B.B.; LastName, C.C. Article Title. Journal Name Year, Article Number, Page Range. ISBN 978-3-03936-720-7 (Hbk) ISBN 978-3-03936-721-4 (PDF) c 2020 by the authors. Articles in this book are Open Access and distributed under the Creative Commons Attribution (CC BY) license, which allows users to download, copy and build upon published articles, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. The book as a whole is distributed by MDPI under the terms and conditions of the Creative Commons license CC BY-NC-ND. Contents About the Editor .............................................. vii Preface to ”Radiolabelled Molecules for Brain Imaging with PET and SPECT” ........
    [Show full text]
  • Réglementation De La Pharmacie
    R E C U E I L D E T E X T E S S U R L A P H A R M A C I E Mis à jour le 13 février 2017 par l’Inspection de la pharmacie P R É A M B U L E La réglementation relative à la pharmacie en vigueur en Nouvelle-Calédonie résulte de la coexistence des dispositions adoptées par la Nouvelle-Calédonie au titre de ses compétences en matières d’hygiène publique, de santé et de professions de la pharmacie1, et de celles adoptées par l’Etat au titre de ses compétences en matières de garanties des libertés publiques, de droit civil et de droit commercial2. Sur le contenu du recueil En 1954, la Nouvelle-Calédonie s’est vue étendre les articles L. 511 à L. 520 et L. 549 à L. 665 de l’ancien Livre V relatif à la Pharmacie du code de la santé publique métropolitain par la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du Code de la santé publique relatives à l'exercice de la pharmacie3, dont les modalités d’application ont été fixées par le décret modifié n° 55-1122 du 16 août 1955 fixant les modalités d'application de la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du code de la santé publique relatives à l'exercice de la pharmacie4. Depuis sont intervenues la loi- cadre Defferre5, la loi référendaire de 19886 et la loi organique n° 99-209 du 19 mars 1999 dont les apports ont eu pour résultat le transfert de ces articles de la compétence de l’Etat à la compétence de la Nouvelle-Calédonie, permettant à celle-ci de s’en approprier et de les modifier à sa guise par des délibérations du congrès de la Nouvelle-Calédonie7.
    [Show full text]
  • 29. Produits Chimiques Organiques
    29 Chapitre 29 Produits chimiques organiques Considérations générales Le Chapitre 29 ne comprend, en principe, que des composés de constitution chimique dé- finie présentés isolément, sous réserve toutefois des dispositions de la Note 1 du Chapitre. A) Composés de constitution chimique définie (Note 1 du Chapitre) Un composé de constitution chimique définie présenté isolément est une substance consti- tuée par une espèce moléculaire (covalente ou ionique, notamment) dont la composition est définie par un rapport constant entre ses éléments et qui peut être représentée par un diagramme structural unique. Dans un réseau cristallin, l'espèce moléculaire correspond au motif répétitif. Les composés de constitution chimique définie présentés isolément contenant des subs- tances qui ont été ajoutées délibérément pendant ou après leur fabrication (y compris la purification) sont exclus du présent Chapitre. Par conséquent, un produit constitué par exemple par de la saccharine mélangée avec du lactose afin qu'il puisse être utilisé comme édulcorant, est exclu du présent Chapitre (voir la Note explicative du no 2925). Ces composés peuvent contenir des impuretés (Note 1 a). Le libellé du no 2940 fait excep- tion à cette règle car, en ce qui concerne les sucres, il restreint la portée de la position aux sucres chimiquement purs. Le terme "impuretés" s'applique exclusivement aux substances dont la présence dans le composé chimique distinct résulte exclusivement et directement du procédé de fabrication (y compris la purification). Ces substances peuvent résulter de l'un quelconque des élé- ments intervenant au cours de la fabrication, et qui sont essentiellement les suivants: a) matières de départ non converties, b) impuretés se trouvant dans les matières de départ, c) réactifs utilisés dans le procédé de fabrication (y compris la purification), d) sous-produits.
    [Show full text]
  • ID-75-77 If the United States Is to Develop an Effective International
    UN1TED STATES REPO@F !FfyT’?f?8T CONGRESSOfb7J+ JUL 3 I ?wl llillllllllllillll1lll1lll~llll~~l LM096967 “-...-. x-- If The Un’ited States Is To Develop An Effective International Narcotics Control Program, Much More Must Be Done In this Feport GAO examines U.S. diplomatic actions and other activities aimed at halting International production and trafficking of illicit narcotics and at stopping their flow into the United States. BY THE COMPTROLLER GENERAL OF THE UNITED STATES @ ID-75-77 COMPTROLLER GENERAL OF THE UNITED STATES WASHINGTON. D.C. X’S48 E-175425 To the President of the Senate and the br Speaker of the House of Representatives This report examines U.S. international narcotics control efforts and discusses improvements needed in opera- tions, activities, and related policies and objectives. We made our review pursuant to the Budget and Accounting Act, 1921 (31 U.S.C. 53), and the Accounting and Auditing Act of 1950 (31 U.S.C. 67). We are sending copies of this report to the Director, Office of Management and Budget; the Secretary of State; the Attorney General; and the Administrator, Agency for Inter- national Development. Comptroller General of the United States r- t Contents Page DIGEST i CHAPTER 1 INTRODUCTION AND BACKGROUND General overview Funding Cabinet Committee Scope of review 2 U.S. OPIUM POLICY 8 U.S. opium policy unclear 8 Evolution of an alleged opium shortage 10 Increasing medicinal opiate supplies 13 Agency comments and our evaluation 18 Conclusions 22 Recommendation 22 3 ILLICIT NARCOTICS PRODUCTION AND TRAFFICKING
    [Show full text]
  • 付表 ⅠA 指定を受けた医薬の有効成分 Annex ⅠA Designated
    付表ⅠA 指定を受けた医薬の有効成分 Annex ⅠA Designated Pharmaceutical Active Ingredients 号(Sub-heading) 品名 Description 2818.30 アルゲルドラート algeldrate 2833.22 アルスルフ alusulf 2842.10 アルマシラート almasilate 2842.10 シマルドラート simaldrate 2842.90 硫酸アルマドラ ート almadrate sulfate 2842.90 アルマガート almagate 2842.90 カルバルドラード carbaldrate 2842.90 ヒドロタルシト hydrotalcite 2842.90 マガルドラート magaldrate 2843.30 オーラノフィン auranofin 2843.30 金チオグリカニド aurothioglycanide 2843.30 金チオりんご酸ナトリウム sodium aurothiomalate 2843.30 金チオ硫酸ナトリウム sodium aurotiosulfate 2843.90 カルボプラチン carboplatin 2843.90 シスプラチン cisplatin 2843.90 デキソルマプラチン dexormaplatin 2843.90 エンロプラチン enloplatin 2843.90 イプロプラチン iproplatin 2843.90 ロバプラチン lobaplatin 2843.90 ミボプラチン miboplatin 2843.90 ネダプラチン nedaplatin 2843.90 オルマプラチン ormaplatin 2843.90 オキサリプラチン oxaliplatin 2843.90 セブリプラチン sebriplatin 2843.90 スピロプラチン spiroplatin 2843.90 ゼニプラチン zeniplatin 2844.40 アルツモマブ altumomab 2844.40 塩化セシウム(131Cs) cesium (131 Cs) chloride 2844.40 クロルメロドリン(197Hg) chlormerodrin (197 Hg) 2844.40 シアノコバラミン(57Co) cyanocobalamin (57 Co) 2844.40 シアノコバラミン(58Co) cyanocobalamin (58 Co) 2844.40 シアノコバラミン(60Co) cyanocobalamin (60 Co) 2844.40 エチオダイズド油(131I) ethiodized oil (131 I) 2844.40 くえん酸第二鉄(59Fe)注射液 ferric (59 Fe) citrate in 2844.40 フィブリノゲン(125I) fibrinogen (125 I) 2844.40 フルデオキシグルコー ス(18F) fludeoxyglucose ( 18 F) 2844.40 フルオロドパ(18F) fluorodopa (18 F) 2844.40 くえん酸ガリウム(67Ga) gallium (67 Ga) citrate 2844.40 金コロイド(198Au) gold (198 Au), colloidal 2844.40 イオベングアン(131I) iobenguane (131 I) 2844.40 よう化人血清アルブミン(125I) iodinated (125 I) human serum albumin 2844.40 よう化人血清アルブミン(131I) iodinated
    [Show full text]
  • Interactions Fonctionnelles Entre Récepteurs À Peptide RF-Amide Et Caractérisation De Ligands Bifonctionnels Des Récepteurs Mu Opioïde Et NPFF
    UNIVERSITÉ DE STRASBOURG ÉCOLE DOCTORALE des Sciences de la Vie et de la Santé UMR 7242 -Biotechnologie et signalisation cellulaire THÈSE En vue de l’obtention du DOCTORAT DE L’UNIVERSITE DE STRASBOURG Discipline : Pharmacologie Etude des interactions fonctionnelles entre les récepteurs à peptide RF-amide et caractérisation de ligands bifonctionnels des récepteurs mu opioïde et NPFF Présentée et soutenue par Armand DRIEU LA ROCHELLE Le 12 avril 2018 JURY Dr. SIMONIN Frédéric, Directeur de recherche, université de Strasbourg Directeur de Thèse Dr MORISSET-LOPEZ Séverine, Chargé de recherche, CBM, Orléans Rapporteur externe Dr. BELTRAMO Massimiliano, Directeur de recherche, Centre INRA Val de Loire Rapporteur externe Pr. GAVERIAUX-RUFF Claire, Professeur de l’université de Strasbourg Examinateur interne Remerciements Je souhaite tout d’abord adresser mes remerciements aux membres du jury pour avoir accepté d’évaluer mon travail, Dr. Séverine Morisser-Lopez, Pr. Claire Gavériaux-Ruff, Dr. Massimiliano Beltramo et Dr. Didier Rognan. Je voudrais également remercier Frédéric Simonin pour m’avoir accueilli dans son équipe, et pour son soutien dans la préparation du concours de l’école doctorale en Master 2. Merci pour le partage de tes connaissances, tant sur les mécanismes de l’hyperalgésie induite par les opiacés que sur les orchidées sauvages d’Alsace, merci pour ta disponibilité et pour l’autonomie que tu m’as accordée dans ces divers projets. Ma gratitude et ma reconnaissance vont à Brigitte Ilien, ton exigence et ta rigueur accompagnées de ta bonne humeur resteront un exemple pour moi. Merci à toi pour ces longues conversations de pharmacologie moléculaire, en particulier sur le FRET, qui m’ont tant appris et m’auront permis de construire un regard critique sur ce travail de thèse.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Identification of Four Novel Prognosis Biomarkers and Potential Therapeutic Drugs for Human Colorectal Cancer by Bioinformatics Analysis
    Available online at www.jbr-pub.org.cn Open Access at PubMed Central The Journal of Biomedical Research, 2021 35(1): 21–35 Original Article Identification of four novel prognosis biomarkers and potential therapeutic drugs for human colorectal cancer by bioinformatics analysis Zhen Sun1,2, Chen Liu1, Steven Y. Cheng1,3,✉ 1Department of Medical Genetics, 2Department of Pathology and Pathophysiology, 3Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, Jiangsu 211166, China. Abstract Colorectal cancer (CRC) is one of the most deadly cancers in the world with few reliable biomarkers that have been selected into clinical guidelines for prognosis of CRC patients. In this study, mRNA microarray datasets GSE113513, GSE21510, GSE44076, and GSE32323 were obtained from the Gene Expression Omnibus (GEO) and analyzed with bioinformatics to identify hub genes in CRC development. Differentially expressed genes (DEGs) were analyzed using the GEO2R tool. Gene ontology (GO) and KEGG analyses were performed through the DAVID database. STRING database and Cytoscape software were used to construct a protein-protein interaction (PPI) network and identify key modules and hub genes. Survival analyses of the DEGs were performed on GEPIA database. The Connectivity Map database was used to screen potential drugs. A total of 865 DEGs were identified, including 374 upregulated and 491 downregulated genes. These DEGs were mainly associated with metabolic pathways, pathways in cancer, cell cycle and so on. The PPI network was identified with 863 nodes and 5817 edges. Survival analysis revealed that HMMR, PAICS, ETFDH, and SCG2 were significantly associated with overall survival of CRC patients.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0221277 A1 Menzaghi Et Al
    US 20140221277A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0221277 A1 Menzaghi et al. (43) Pub. Date: Aug. 7, 2014 (54) METHOD FOR ELEVATING PROLACTIN IN tion No. 12/300,595, filed on Apr. 22, 2009, now Pat. MAMMALS No. 8,217,000, filed as application No. PCT/US2007/ 012285 on May 22, 2007. (71)71) ApplicantsApplicants: MStFrederi Le.g.,M hi, RVe, S. SterNY E.(US) ); (60) Provisional application No. 60/808,677, filed on May (US); Derek T. Chalmers, Riverside, CT 26, 2006. (US) Publication Classification (72) Inventors: Frederique Menzaghi, Rye, NY (US); (51) Int. Cl. Michael E. Lewis, West Chester, PA A638/07 (2006.01) (US); Derek T. Chalmers, Riverside, CT A6II 45/06 (2006.01) (US) (52) U.S. Cl. CPC ................. A61 K38/07 (2013.01); A61K 45/06 (73) Assignee: CARATHERAPEUTICS, INC., (2013.01) SHELTON, CT (US) USPC ............................. 514/4.7: 514/7.3; 514/11.5 (21) Appl. No.: 14/087,142 (57) ABSTRACT Methods for elevating and stabilizing prolactin levels in a (22) Filed: Nov. 22, 2013 mammal including methods of treating disorders and condi tions associated with reduced serum levels of prolactin are O O provided. Also provided are methods of using certain Syn Related U.S. Application Data thetic tetrapeptide amides which are peripherally selective (63) Continuation of application No. 13/543,128, filed on kappa opioid receptor agonists to elevate or stabilize serum Jul. 6, 2012, now abandoned, Continuation of applica prolactin levels. Patent Application Publication Aug. 7, 2014 Sheet 1 of 7 US 2014/0221277 A1 Figure 1: Arithmetic Mean Changes from Baseline (Pre dose) in Serum Prolactin Concentrations Following a 1 hour IV Infusion in Male Subjects (Part A) O 2 A.
    [Show full text]
  • The Effect of Harvest Date and Pre-Storage Drying Methods On
    AN ABSTRACT OF THE THESIS OF Majid Seddigh for the degree of Master of Science in Crop Science presented on April 4, 1980 Title: The Effect of Harvest Date and Pre Storage Drying_ Methods on Capsule Thebaine Yield, Seed Oil Yield and Seed Germination of Two Accessions of Papaver Vacteatum Andl. Abstract approved: Redacted for privacy r Gary 00. Jollf A field study was conducted in 1978 and 1979 at the Hyslop Crop Science Field Laboratory near Corvallis, Oregon, to determine the opti- mum capsule harvest date of Papaver bracteatum Lind. for thebaine yield and oil yield, while maintaining an acceptable percentage of seed ger- mination. Accessions PI 383309 and PI 381607 were chosen for this study because of their superior yield characteristics. The effects of pre-storage drying of harvested plant materials on the yields and seed germination were studied in the second year of the experiment. Both accessions responded similarly to all treatments. The effects of harvest dates on the yield components and seed germination were com- parable in the two years of the study except for the seed yield.The difference for the seed yield was due to earlier capsule maturity in 1979 that resulted in earlier seed shattering in that year. Drying of the harvested plant materials in a dryer immediately after harvest did not significantly affect the oil and thebaine yields or the percentage of seed germination. Although the data for the thebaine concentration of the capsules in 1978 were of questionable accuracy, capsule thebaine yield was not significantly different for the harvest dates later than four weeks after petal opening.
    [Show full text]
  • Cardiac Ryr N-Terminal Region Biosensors for FRET-Based High-Throughput Screening
    bioRxiv preprint doi: https://doi.org/10.1101/2021.02.07.430153; this version posted February 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Cardiac RyR N-terminal region biosensors for FRET-based high-throughput screening Jingyan Zhang1, Siobhan M. Wong King Yuen,2 Jacob A. Schwarz1, Levy M. Treinen1, Ching-Chieh Tung2, Robyn T. Rebbeck1, Kaja Berg3, Bengt Svensson1, Courtney C. Aldrich3, David D. Thomas1, Filip Van Petegem2, and Razvan L. Cornea1* 1Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN 55455, USA. 2Department of Biochemistry and Molecular Biology, Life Sciences Institute, University of British Columbia,V6T 1Z3 Vancouver, BC, Canada. 3Department of Medicinal Chemistry, University of Minnesota, Minneapolis, MN, 55455, USA. Corresponding author: Razvan L. Cornea Email: [email protected] Running title: FRET biosensor constructs for RyR-targeted drug discovery Keywords: Ryanodine receptor; N-terminal region; FRET; fluorescence lifetime; high-throughput screening; myopathy. bioRxiv preprint doi: https://doi.org/10.1101/2021.02.07.430153; this version posted February 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract failure (HF) (9-13). Physiologically, the opening and closing of RyR channels are tightly regulated The N-terminal region (NTR) of the ryanodine by small molecules, ions, and proteins(14), many receptor (RyR) calcium channels is critical to the of them binding to the enormous RyR cytoplasmic 2+ regulation of Ca release during excitation- portion, with functional effects allosterically contraction coupling.
    [Show full text]